Development Milestone Payment. Dosing of first patient in a Phase 1 Clinical Study [*** ] Dosing of first patient in a Phase 2 Clinical Study* [*** ] Dosing of first patient in a Phase 3 Clinical Study [*** ] Date of filing of BLA [*** ] Date of receipt of Regulatory Approval in [***] [*** ] Date of receipt of Regulatory Marketing Approval in [***] [*** ] Date of receipt of Regulatory Marketing Approval in [***] [*** ] 3 [***] “Cytotoxic Compound” [***] ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. If a clinical milestone is achieved and any previous clinical milestone has not yet been achieved for any reason, notwithstanding anything herein to the contrary such previous milestone(s) shall be deemed to have been achieved and the corresponding Development Milestone Payment set forth in the table above shall be payable simultaneously with the Development Milestone Payment for the achievement of the subsequent Milestone. All Development Milestone Payments shall be non-refundable and noncreditable.
Development Milestone Payment. Within **** following ****, AveXis shall pay to AskBio Six Hundred Thousand Dollars ($600,000) (the “Milestone Payment”). The Milestone Payment will be payable only once regardless of (a) whether such milestone is achieved by more than one Licensed Product and (b) whether such milestone is achieved by AveXis, or any Sublicensee (or any of their respective permitted sublicensees). The Milestone Payment shall ****. For avoidance of doubt, the Milestone Payment remains in effect on a country-by-country basis until the later of ****.
Development Milestone Payment. Coherus or its Affiliate shall pay a development milestone payment to Genentech for the first Licensed Product to achieve the development milestone event set forth below. Coherus or its Affiliate shall notify Genentech in writing within fifteen (15) calendar days of achieving such event, and Coherus or its Affiliate shall make the development milestone payment to Genentech within thirty (30) calendar days of achieving such event.
Development Milestone Payment. The table in Section 6.1(c) of the License Agreement is hereby deleted and replaced in its entirety with the following table: Development Milestone Event Development Milestone Payment (in Dollars)
Development Milestone Payment. In partial consideration of the rights granted by Licensor to Licensee hereunder on the Licensed Technology as set out in Section 7.1, Licensee shall pay to Licensor a one-time milestone payment of twenty-five million Dollars ($25 million) in cash upon the first Regulatory Approval of a Licensed Product by the FDA for Myasthenia Gravis. Licensor will notify Licensee in writing upon the achievement of such milestone event. Licensee shall pay to Licensor the milestone payment within [***] days upon receipt of an invoice from Licensor.
Development Milestone Payment. (a) Licensee shall make the non-refundable, non-creditable milestone payments to Tetraphase set forth in the table below, each payable once only, no later than [**] days after the earliest date on which the corresponding milestone event has first been achieved by any Licensee Entity with respect to the first Licensed Product to achieve such milestone event. Milestone Event Milestone Payment [**] [**] [**] [**] [**] [**] [**] [**]
Development Milestone Payment. (i) If, on or prior to the last date of provision of Symphion-related Seller Services, as defined in and pursuant to the Transition Services Agreement (the “Development Due Date”), Parent achieves the Development Milestone, then Buyer shall pay the Development Milestone Payment in accordance with this Section 2.07(b). If the Development Milestone is not achieved by the Development Due Date, then Parent shall, or shall cause its Affiliates to, within ten (10) Business Days of the Development Due Date, deliver to Buyer all books and records, including any work in progress, held by Parent or its Affiliates related to the achievement of the Development Milestone.
Development Milestone Payment. Acquiror shall pay the Development Milestone Payment to the Exchange Agent (for distribution to the Company Securityholders) within [*] calendar days [*].
Development Milestone Payment. During the Term, upon the achievement by or on behalf of a Party or its Affiliates or Sublicensees of any milestone event set forth below in Table 6.1(b) (Development Milestone Payments) (each, a “Development Milestone Event”) for the Licensed Product, the achieving Party will notify the other Party promptly after the occurrence thereof, and Lian will pay Lyra a non-refundable, non-creditable, and not subject to set-off, milestone payment set forth in the table below (each, a “Development Milestone Payment”) no later than [***] days after its achievement of such milestone event. Each of the milestone payments set forth below in Table 6.1(b) (Development Milestone Payment) is payable [***]. Table 6.1(b) (Development Milestone Payments) Development Milestone Event Development Milestone Payment (in Dollars)
Development Milestone Payment. A one-time payment of the Development Milestone Payment payable in accordance with Section 1.17.
